Literature DB >> 21660632

[Intensive care and inflammatory bowel diseases (IBD). The severe and fulminant flare].

J Büning1, K Fellermann.   

Abstract

Inflammatory bowel disease (IBD) is a non-curable disease. Although we seem to have a definitive surgical solution for ulcerative colitis, patients are at risk of suffering from acute and chronic pouchitis as well as peri- and postoperative complications. In Crohn's disease medical treatment is able to prolong surgery-free survival, but no definitive healing strategy is as yet at hand. Moreover, effective medication exposes patients to potentially life-threatening complications. The severely compromised patient in particular needs careful surveillance and requires a balanced treatment strategy endorsed by gastroenterologists and surgeons. Treatment is still aimed at suppressing immune mechanisms and is far from being causal. Nevertheless, this approach has resulted in a reduction in surgical procedures and hospitalizations. The following overview covers special issues related to strategies for severe and fulminant flares of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21660632     DOI: 10.1007/s00108-010-2797-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  44 in total

Review 1.  Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander?

Authors:  Garrett Lawlor; Alan C Moss
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

2.  [Life-threatening complications of Crohn's disease and ulcerative colitis: a systematic analysis of admissions to an ICU during 18 years].

Authors:  W Huber; G Herrmann; T Schuster; V Phillip; B Saugel; C Schultheiss; J Hoellthaler; J Gaa; M Hartel; R M Schmid; W Reindl
Journal:  Dtsch Med Wochenschr       Date:  2010-03-31       Impact factor: 0.628

3.  Vascular complications of inflammatory bowel disease.

Authors:  R W Talbot; J Heppell; R R Dozois; R W Beart
Journal:  Mayo Clin Proc       Date:  1986-02       Impact factor: 7.616

4.  An experience of ulcerative colitis. I. Toxic dilation in 55 cases.

Authors:  K N Jalan; W Sircus; W I Card; C W Falconer; C B Bruce; G P Crean; J P McManus; W P Small; A N Smith
Journal:  Gastroenterology       Date:  1969-07       Impact factor: 22.682

5.  Outcome of cytomegalovirus infections in patients with inflammatory bowel disease.

Authors:  K A Papadakis; J K Tung; S W Binder; L Y Kam; M T Abreu; S R Targan; E A Vasiliauskas
Journal:  Am J Gastroenterol       Date:  2001-07       Impact factor: 10.864

Review 6.  Review article: Infliximab therapy for inflammatory bowel disease--seven years on.

Authors:  P Rutgeerts; G Van Assche; S Vermeire
Journal:  Aliment Pharmacol Ther       Date:  2006-02-15       Impact factor: 8.171

7.  Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies.

Authors:  Takuya Yoshino; Hiroshi Nakase; Satoru Ueno; Norimitsu Uza; Satoko Inoue; Sakae Mikami; Minoru Matsuura; Katsuyuki Ohmori; Takaki Sakurai; Satoshi Nagayama; Suguru Hasegawa; Yoshiharu Sakai; Tsutomu Chiba
Journal:  Inflamm Bowel Dis       Date:  2007-12       Impact factor: 5.325

8.  Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis.

Authors:  G T Ho; H M Lee; G Brydon; T Ting; N Hare; H Drummond; A G Shand; D C Bartolo; R G Wilson; M G Dunlop; I D Arnott; J Satsangi
Journal:  Am J Gastroenterol       Date:  2009-02-17       Impact factor: 10.864

9.  Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity.

Authors:  F Carbonnel; A Lavergne; M Lémann; A Bitoun; P Valleur; P Hautefeuille; A Galian; R Modigliani; J C Rambaud
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

Review 10.  Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis.

Authors:  J Shen; Z H Ran; J L Tong; S D Xiao
Journal:  Aliment Pharmacol Ther       Date:  2007-09-01       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.